Citations (118)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (18)
Gen Lu, Fei Pan, Xiaotong Li, Zehui Zhu, Lei Zhao, Ya Wu, Wenli Tian, Wenjun Peng & Jinling Liu. (2023) Virtual screening strategy for anti-DPP-IV natural flavonoid derivatives based on machine learning. Journal of Biomolecular Structure and Dynamics 0:0, pages 1-15.
Read now
Read now
H.L. Katzeff, D. Williams-Herman, L. Xu, G.T. Golm, H. Wang, Q. Dong, J.R. Johnson, E.A. O’Neill, K.D. Kaufman, S.S. Engel & B.J. Goldstein. (2015) Long-term efficacy of sitagliptin as either monotherapy or add-on therapy to metformin: improvement in glycemic control over 2 years in patients with type 2 diabetes. Current Medical Research and Opinion 31:6, pages 1071-1077.
Read now
Read now
Sri Harsha Tella & Marc S Rendell. (2015) DPP-4 inhibitors: focus on safety. Expert Opinion on Drug Safety 14:1, pages 127-140.
Read now
Read now
Ching-Jung Hsieh & Feng-Chih Shen. (2014) The durability of sitagliptin in elderly patients with type 2 diabetes. Clinical Interventions in Aging 9, pages 1905-1911.
Read now
Read now
Tse-Ying Chen & Ching-Jung Hsieh. (2014) Real-World Effectiveness of Sitagliptin as Add-On Therapy in Patients With Type 2 Diabetes Mellitus. Postgraduate Medicine 126:3, pages 205-215.
Read now
Read now
Vinay S Eligar & Stephen C Bain. (2013) A review of sitagliptin with special emphasis on its use in moderate to severe renal impairment. Drug Design, Development and Therapy 7, pages 893-903.
Read now
Read now
Miyako Kishimoto. (2013) Teneligliptin: a DPP-4 inhibitor for the treatment of type 2 diabetes. Diabetes, Metabolic Syndrome and Obesity 6, pages 187-195.
Read now
Read now
Marc Rendell, Andjela Drincic & Radha Andukuri. (2012)
Alogliptin benzoate for the treatment of type 2 diabetes. Expert Opinion on Pharmacotherapy 13:4, pages 553-563.
Read now
Read now
Kishore VL Parsa & Manojit Pal. (2011) Preclinical development of dipeptidyl peptidase IV inhibitor alogliptin: a brief overview. Expert Opinion on Drug Discovery 6:8, pages 855-869.
Read now
Read now
Baptist Gallwitz. (2011) Sitagliptin and metformin combination therapy for the treatment of Type 2 diabetes. Expert Review of Endocrinology & Metabolism 6:4, pages 543-556.
Read now
Read now
Baptist Gallwitz. (2010) New treatments in the management of type 2 diabetes: a critical appraisal of saxagliptin. Diabetes, Metabolic Syndrome and Obesity 3, pages 117-124.
Read now
Read now
Qiaoyi Zhang, Srini Rajagopalan, Panagiotis Mavros, Samuel S. Engel, Michael J. Davies, Donald Yin & Larry Radican. (2010) Baseline characteristic differences between patients prescribed sitagliptin vs. other oral antihyperglycemic agents: analysis of a US electronic medical record database. Current Medical Research and Opinion 26:7, pages 1697-1703.
Read now
Read now
Shannon A Miller, Erin L St Onge & J Roger Accardi. (2009) Sitagliptin as combination therapy in the treatment of type 2 diabetes mellitus. Diabetes, Metabolic Syndrome and Obesity 2, pages 23-30.
Read now
Read now
Radha Andukuri, Andjela Drincic & Marc Rendell. (2009) Alogliptin: a new addition to the class of DPP-4 inhibitors. Diabetes, Metabolic Syndrome and Obesity 2, pages 117-126.
Read now
Read now
M. Alba, D. Sheng, Y. Guan, D. Williams-Herman, P. Larson, J.R. Sachs, N. Thornberry, G. Herman, K.D. Kaufman & B.J. Goldstein. (2009) Sitagliptin 100 mg daily effect on DPP-4 inhibition and compound-specific glycemic improvement. Current Medical Research and Opinion 25:10, pages 2507-2514.
Read now
Read now
Tsuneyuki Oku, Mariko Nakamura, Ayako Takasugi, Michiru Hashiguchi-Ishiguro, Kenichi Tanabe & Sadako Nakamura. (2009) Effects of cake made from whole soy powder on postprandial blood glucose and insulin levels in human subjects. International Journal of Food Sciences and Nutrition 60:sup4, pages 224-231.
Read now
Read now
Bo Ahrén. (2008) Emerging dipeptidyl peptidase-4 inhibitors for the treatment of diabetes. Expert Opinion on Emerging Drugs 13:4, pages 593-607.
Read now
Read now
Joan K Bardsley & Robert E Ratner. (2008) Sitagliptin: an oral agent for glucose control. Expert Review of Endocrinology & Metabolism 3:6, pages 691-697.
Read now
Read now
Articles from other publishers (100)
Cigdem Kahraman & Iffet Irem Tatli Cankaya. 2023. Methods for Preclinical Evaluation of Bioactive Natural Products. Methods for Preclinical Evaluation of Bioactive Natural Products
70
100
.
Andrew G. McCloskey, Michael G. Miskelly, Ryan A. Lafferty, Peter R. Flatt & Aine M McKillop. (2023) Antidiabetic actions of GPR55 agonist Abn-CBD and sitagliptin in obese-diabetic high fat fed mice. Biochemical Pharmacology 208, pages 115398.
Crossref
Crossref
Vera M. Kosman, Marina V. Karlina, Natalia M. Faustova, Valery G. Makarov & Marina N. Makarova. (2021) Comparison of biomarker and chromatographic analytical approaches to pharmacokinetic study of sitagliptin. Biopharmaceutics & Drug Disposition 43:1, pages 3-10.
Crossref
Crossref
Baorui Li, Lei Fu, Ruchia Kojima, Ayaka Yamamoto, Tomoya Ueno & Toshiro Matsui. (2021) Theaflavins prevent the onset of diabetes through ameliorating glucose tolerance mediated by promoted incretin secretion in spontaneous diabetic Torii rats. Journal of Functional Foods 86, pages 104702.
Crossref
Crossref
Isma Haq, Kaseb Alanazi, Joanna Czulak, Sabrina Di Masi, Elena Piletska, Adnan Mujahid, Tajamal Hussain, Sergey A. Piletsky & Alvaro Garcia-Cruz. (2021) Determination of sitagliptin in human plasma using a smart electrochemical sensor based on electroactive molecularly imprinted nanoparticles. Nanoscale Advances 3:14, pages 4276-4285.
Crossref
Crossref
Stavroula A. Paschou, Gerasimos Siasos, Evanthia Bletsa, Panagiota K. Stampouloglou, Evangelos Oikonomou, Alexios S. Antonopoulos, Konstantinos Batzias, Vasiliki Tsigkou, Konstantinos Mourouzis, Andromachi Vryonidou, Nikolaos Tentolouris, Manolis Vavouranakis & Dimitrios Tousoulis. (2020) The Effect of DPP-4i on Endothelial Function and Arterial Stiffness in Patients with Type 2 Diabetes: A Systematic Review of Randomized Placebo-controlled Trials. Current Pharmaceutical Design 26:46, pages 5980-5987.
Crossref
Crossref
Patrick Mäder & Lars Kattner. (2020) Sulfoximines as Rising Stars in Modern Drug Discovery? Current Status and Perspective on an Emerging Functional Group in Medicinal Chemistry. Journal of Medicinal Chemistry 63:23, pages 14243-14275.
Crossref
Crossref
Wen Han, Yao Li, Jiangting Cheng, Jing Zhang, Dingwen Chen, Mingqiao Fang, Guangheng Xiang, Yanqing Wu, Hongyu Zhang, Ke Xu, Hangxiang Wang, Ling Xie & Jian Xiao. (2020) Sitagliptin improves functional recovery via GLP‐1R‐induced anti‐apoptosis and facilitation of axonal regeneration after spinal cord injury. Journal of Cellular and Molecular Medicine 24:15, pages 8687-8702.
Crossref
Crossref
Gasparyan Hrachik, Buloyan Sona, Karapetyan Luiza, Harutyunyan Hayk, Antonyan Alvard, Sharoyan Svetlana & Mardanyan Sona. (2020) Mitigation with plant ethanol extracts of STZ-induced histopathological injuries in the tissues of laboratory rats. Global Journal of Biotechnology and Biomaterial Science 6:1, pages 001-006.
Crossref
Crossref
M. Shaheer Malik, Saleh A. Ahmed, Ismail I. Althagafi, Mohammed Azam Ansari & Ahmed Kamal. (2020) Application of triazoles as bioisosteres and linkers in the development of microtubule targeting agents. RSC Medicinal Chemistry 11:3, pages 327-348.
Crossref
Crossref
Qi Ge, Liang Chen, Yi Yuan, Lanlan Liu, Fan Feng, Peng Lv, Shangshang Ma, Keping Chen & Qin Yao. (2020) Network Pharmacology-Based Dissection of the Anti-diabetic Mechanism of Lobelia chinensis. Frontiers in Pharmacology 11.
Crossref
Crossref
Momir Mikov, Nebojša Pavlović, Bojan Stanimirov, Maja Đanić, Svetlana Goločorbin-Kon, Karmen Stankov & Hani Al-Salami. (2019) DPP-4 Inhibitors: Renoprotective Potential and Pharmacokinetics in Type 2 Diabetes Mellitus Patients with Renal Impairment. European Journal of Drug Metabolism and Pharmacokinetics 45:1, pages 1-14.
Crossref
Crossref
Kalicharan Sharma, Nazia Neshat, Shweta Sharma, Namita Giri, Apeksha Srivastava, Faisal Almalki, Khalid Saifullah, Md. Mumtaz Alam, Mohammad Shaquiquzzaman & Mymoona Akhter. (2019)
Identification of novel selective
Mtb
‐DHFR inhibitors as antitubercular agents through structure‐based computational techniques
. Archiv der Pharmazie 353:2.
Crossref
Crossref
Jung Min Lee, In Kyung Yoo, Jae Min Lee, Seung Han Kim, Hyuk Soon Choi, Eun Sun Kim, Bora Keum, Yeon Seok Seo, Yoon Tae Jeen, Hoon Jai Chun, Hong Sik Lee, Soon Ho Um & Chang Duck Kim. (2019) Dipeptidyl-peptidase-4 (DPP-4) inhibitor ameliorates 5-flurouracil induced intestinal mucositis. BMC Cancer 19:1.
Crossref
Crossref
Daryl J. Fediuk, Kyle Matschke, Yali Liang, Kathleen B. Pelletier, Hua Wei, Haihong Shi, Almasa Bass, Anne Hickman, Steven G. Terra, Susan Zhou, Rajesh Krishna & Vaishali Sahasrabudhe. (2019) Bioequivalence of Ertugliflozin/Sitagliptin Fixed‐Dose Combination Tablets and Coadministration of Respective Strengths of Individual Components. Clinical Pharmacology in Drug Development 8:7, pages 884-894.
Crossref
Crossref
Niannian Wang, Feifei Zhu, Mingxiang Shen, Lipeng Qiu, Min Tang, Hengchuan Xia, Liang Chen, Yi Yuan, Shangshang Ma & Keping Chen. (2019) Network pharmacology-based analysis on bioactive anti-diabetic compounds in Potentilla discolor bunge. Journal of Ethnopharmacology 241, pages 111905.
Crossref
Crossref
S W Kisnawaty, P Nityasewaka, B A R Sukma, A V Putrinadia, T Ma’rifah, D G Tamtomo & D Indarto. (2019) Alkaloid Fraction of Litsea glutinosa Leaves Provides an Important Precursor for Inhibition of Dipeptidyl Peptidase 4 Activity. IOP Conference Series: Materials Science and Engineering 546:6, pages 062013.
Crossref
Crossref
Yumie Takeshita, Yuki Kita, Ken‐ichiro Kato, Takehiro Kanamori, Hirofumi Misu, Shuichi Kaneko & Toshinari Takamura. (2018) Effects of metformin and alogliptin on body composition in people with type 2 diabetes. Journal of Diabetes Investigation 10:3, pages 723-730.
Crossref
Crossref
Emily D. Parker, Eric T. Wittbrodt, Jeffrey T. McPheeters & Juan P. Frias. (2018) Comparison of healthcare resource utilization and costs in patients with type 2 diabetes initiating dapagliflozin versus sitagliptin. Diabetes, Obesity and Metabolism 21:2, pages 227-233.
Crossref
Crossref
Xiangjun Qiu, Saili Xie, Lei Ye & Ren-ai Xu. (2019) UPLC-MS/MS method for the quantification of ertugliflozin and sitagliptin in rat plasma. Analytical Biochemistry 567, pages 112-116.
Crossref
Crossref
Chunhong Shi, Ru Zhang, Ran Bai, Dan Liu, Yongbo Wang, Xueyang Zhang, Hao Wang & Jianling Du. (2019) Efficacy and safety of sitagliptin added to metformin and insulin compared with voglibose in patients with newly diagnosed type 2 diabetes. Clinics 74, pages e736.
Crossref
Crossref
Ming-rong Zhu, Jie Zhou, Yi Jin, Li-Hui Gao, Ling Li, Jun-Ru Yang, Chun-Mei Lu, Qi Hua Zhao & Ming-jin Xie. (2018) A manganese-salen complex as dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes. International Journal of Biological Macromolecules 120, pages 1232-1239.
Crossref
Crossref
Yuya Tsurutani, Kazuki Nakai, Kosuke Inoue, Kosuke Azuma, Sei Mukai, Seitaro Maruyama, Takashi Iizuka, Yoko Matsuzawa, Jun Saito, Masao Omura & Tetsuo Nishikawa. (2018) Comparative study of the effects of ipragliflozin and sitagliptin on multiple metabolic variables in Japanese patients with type 2 diabetes: A multicentre, randomized, prospective, open‐label, active‐controlled study. Diabetes, Obesity and Metabolism 20:11, pages 2675-2679.
Crossref
Crossref
Samuel Dagogo‐Jack, Jie Liu, Roy Eldor, Guillermo Amorin, Jeremy Johnson, Darcy Hille, Yuqin Liao, Susan Huyck, Gregory Golm, Steven G. Terra, James P. Mancuso, Samuel S. Engel & Brett Lauring. (2017)
Efficacy and safety of the addition of ertugliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin and sitagliptin: The
VERTIS SITA2
placebo‐controlled randomized study
. Diabetes, Obesity and Metabolism 20:3, pages 530-540.
Crossref
Crossref
Sam Miller, Tania Krumins, Haojin Zhou, Susan Huyck, Jeremy Johnson, Gregory Golm, Steven G. Terra, James P. Mancuso, Samuel S. Engel & Brett Lauring. (2018) Ertugliflozin and Sitagliptin Co-initiation in Patients with Type 2 Diabetes: The VERTIS SITA Randomized Study. Diabetes Therapy 9:1, pages 253-268.
Crossref
Crossref
Ming-jin Xie, Ming-rong Zhu, Chun-Mei Lu, Yi Jin, Li-Hui Gao, Ling Li, Jie Zhou, Fan-fang Li, Qi Hua Zhao, Hong-Ke Liu, Peter J. Sadler & Carlos Sanchez-Cano. (2017) Synthesis and characterization of oxidovanadium complexes as enzyme inhibitors targeting dipeptidyl peptidase IV. Journal of Inorganic Biochemistry 175, pages 29-35.
Crossref
Crossref
J.J. Song, Q. Wang, M. Du, X.M. Ji & X.Y. Mao. (2017) Identification of dipeptidyl peptidase-IV inhibitory peptides from mare whey protein hydrolysates. Journal of Dairy Science 100:9, pages 6885-6894.
Crossref
Crossref
T. Biftu & R. SinhaRoy. 2017. Comprehensive Medicinal Chemistry III. Comprehensive Medicinal Chemistry III
512
555
.
Sung-Ho Kim, Eunsoo Jung, Min Kyung Yoon, O. Hwan Kwon, Dal-Mi Hwang, Dong-Wook Kim, Junghyun Kim, Sun-Mee Lee & Hyeon Joo Yim. (2016) Pharmacological profiles of gemigliptin (LC15-0444), a novel dipeptidyl peptidase-4 inhibitor, in vitro and in vivo. European Journal of Pharmacology 788, pages 54-64.
Crossref
Crossref
Jung-Fu Chen, Chih-Min Chang, Ming-Chun Kuo, Shih-Chen Tung, Cheng-Feng Tsao & Chia-Jen Tsai. (2016) Impact of baseline body mass index status on glucose lowering and weight change during sitagliptin treatment for type 2 diabetics. Diabetes Research and Clinical Practice 120, pages 8-14.
Crossref
Crossref
Poobalan Naidoo, Jeffrey Wing & Virendra Rambiritch. (2016) Effect of Sitagliptin and Metformin on Prediabetes Progression to Type 2 Diabetes - A Randomized, Double-Blind, Double-Arm, Multicenter Clinical Trial: Protocol for the Sitagliptin and Metformin in PreDiabetes (SiMePreD) Study. JMIR Research Protocols 5:3, pages e145.
Crossref
Crossref
Friederike Remm, Wolfgang-Michael Franz & Christoph Brenner. (2016) Gliptins and their target dipeptidyl peptidase 4: implications for the treatment of vascular disease. European Heart Journal - Cardiovascular Pharmacotherapy 2:3, pages 185-193.
Crossref
Crossref
Akihiro Mori, Kaori Ueda, Peter Lee, Hitomi Oda, Katsumi Ishioka, Toshiro Arai & Toshinori Sako. (2016) Effect of Acarbose, Sitagliptin and combination therapy on blood glucose, insulin, and incretin hormone concentrations in experimentally induced postprandial hyperglycemia of healthy cats. Research in Veterinary Science 106, pages 131-134.
Crossref
Crossref
Yanchan Wei, Shiwen Xia, Conglin He, Wenjuan Xiong & Hongmei Xu. (2016) Highly enantioselective production of a chiral intermediate of sitagliptin by a novel isolate of Pseudomonas pseudoalcaligenes. Biotechnology Letters 38:5, pages 841-846.
Crossref
Crossref
Heng Wan, Defu Zhao, Jie Shen, Lu Lu, Tong Zhang & Zhi Chen. (2016) Comparison of the Effects of Continuous Subcutaneous Insulin Infusion and Add-On Therapy with Sitagliptin in Patients with Newly Diagnosed Type 2 Diabetes Mellitus. Journal of Diabetes Research 2016, pages 1-7.
Crossref
Crossref
Xiaoling Cai, Wenjia Yang, Lingli Zhou, Simin Zhang, Xueyao Han & Linong Ji. (2015) Comparisons of the efficacy of glucose control, lipid profile, and β-cell function between DPP-4 inhibitors and AGI treatment in type 2 diabetes patients: a meta-analysis. Endocrine 50:3, pages 590-597.
Crossref
Crossref
B. Ramesh, N. Manjula, S.R. Bijargi, V.U.M. Sarma & P. Sita Devi. (2015) Comparison of conventional and supported liquid extraction methods for the determination of sitagliptin and simvastatin in rat plasma by LC–ESI–MS/MS. Journal of Pharmaceutical Analysis 5:3, pages 161-168.
Crossref
Crossref
Abdallah Al Eyadeh & Paul E Jennings. (2015) New pharmacological approaches to diabetes management. Practice Nursing 26:3, pages 140-146.
Crossref
Crossref
Miyako Kishimoto & Mitsuhiko Noda. (2014) Additive Effects of Miglitol and Anagliptin on Insulin-Treated Type 2 Diabetes Mellitus: A Case Study. Clinical Drug Investigation 35:2, pages 141-147.
Crossref
Crossref
Ji Hyun Kim. (2015) Effects of Sitagliptin on Insulin and Glucagon Levels in Type 2 Diabetes Mellitus. Diabetes & Metabolism Journal 39:4, pages 304.
Crossref
Crossref
Hyun Min KimJung Soo LimByung-Wan LeeEun-Seok KangHyun Chul LeeBong-Soo Cha. (2015) Optimal Candidates for the Switch from Glimepiride to Sitagliptin to Reduce Hypoglycemia in Patients with Type 2 Diabetes Mellitus. Endocrinology and Metabolism 30:1, pages 84.
Crossref
Crossref
Saujanya Acharya, Raja Reddy Kuppili, Lalith K. Chaganti & Kakoli Bose. 2015. Proteases in Apoptosis: Pathways, Protocols and Translational Advances. Proteases in Apoptosis: Pathways, Protocols and Translational Advances
143
202
.
Chun-Jun Li, Xiao-Juan Liu, Lian Bai, Qian Yu, Qiu-Mei Zhang, Pei Yu & De-Min Yu. (2014) Efficacy and safety of vildagliptin, Saxagliptin or Sitagliptin as add-on therapy in Chinese patients with type 2 diabetes inadequately controlled with dual combination of traditional oral hypoglycemic agents. Diabetology & Metabolic Syndrome 6:1.
Crossref
Crossref
Sinan Wang, Mingbo Su, Jiang Wang, Zeng Li, Lei Zhang, Xun Ji, Jingya Li, Jia Li & Hong Liu. (2014) ( R )-3-Amino-1-((3a S ,7a S )-octahydro-1 H -indol-1-yl)-4-(2,4,5-trifluorophenyl)butan-1-one derivatives as potent inhibitors of dipeptidyl peptidase-4: Design, synthesis, biological evaluation, and molecular modeling. Bioorganic & Medicinal Chemistry 22:23, pages 6684-6693.
Crossref
Crossref
Mohd. Riaz, Imran Imran, Rinu Manuel & Nidhisha K Joseph. (2014) AN OBSERVATIONAL STUDY COMPARING SITAGLIPTIN TO METFORMIN AS A INITIAL MONOTHERAPY IN TYPE 2 DIABETES MELLITUS PATIENTS. Journal of Evolution of Medical and Dental Sciences 3:7, pages 1698-1703.
Crossref
Crossref
Nobuya Inagaki, Hitoshi Onouchi, Hiroki Sano, Nobuo Funao, Shingo Kuroda & Kohei Kaku. (2014) SYR-472, a novel once-weekly dipeptidyl peptidase-4 (DPP-4) inhibitor, in type 2 diabetes mellitus: a phase 2, randomised, double-blind, placebo-controlled trial. The Lancet Diabetes & Endocrinology 2:2, pages 125-132.
Crossref
Crossref
Sri Harsha Tella, Halis Kaan Akturk & Marc Rendell. (2014) Linagliptin for the treatment of Type 2 diabetes. Diabetes Management 4:1, pages 85-101.
Crossref
Crossref
Jiang Wang, Ying Feng, Xun Ji, Guanghui Deng, Ying Leng & Hong Liu. (2013) Synthesis and biological evaluation of pyrrolidine-2-carbonitrile and 4-fluoropyrrolidine-2-carbonitrile derivatives as dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes. Bioorganic & Medicinal Chemistry 21:23, pages 7418-7429.
Crossref
Crossref
Yukihiro Bando, Kazuhide Ishikura, Hideo Kanehara, Keiko Aoki, Azusa Hisada, Daisyu Toya & Nobuyoshi Tanaka. (2013) Determinants of the HbA1c-lowering effect of sitagliptin when added to ongoing insulin therapy in Japanese patients with type 2 diabetes. Diabetology International 4:4, pages 251-256.
Crossref
Crossref
David Kountz. (2013) The Dipeptidyl Peptidase (DPP)-4 Inhibitors for Type 2 Diabetes Mellitus in Challenging Patient Groups. Advances in Therapy 30:12, pages 1067-1085.
Crossref
Crossref
Naoko Tajima, Takashi Kadowaki, Taro Okamoto, Asako Sato, Kotoba Okuyama, Toshiomi Minamide & Juan Camilo Arjona Ferreira. (2013) Sitagliptin added to voglibose monotherapy improves glycemic control in patients with type 2 diabetes. Journal of Diabetes Investigation 4:6, pages 595-604.
Crossref
Crossref
Takashi Kadowaki, Naoko Tajima, Masato Odawara, Toshiomi Minamide, Masaru Kawashima, Daisuke Yanagida, Taro Okamoto & Juan Camilo Arjona Ferreira. (2013) Efficacy and safety of sitagliptin add-on therapy in Japanese patients with type 2 diabetes on insulin monotherapy. Diabetology International 4:3, pages 160-172.
Crossref
Crossref
Susan A Cornell. (2013) A patient-centred approach to treatment with incretin-based agents in patients with type 2 diabetes. Journal of Clinical Pharmacy and Therapeutics 38:3, pages 181-189.
Crossref
Crossref
Juan C. Arjona Ferreira, Dalila Corry, Carl E. Mogensen, Lance Sloan, Lei Xu, Gregory T. Golm, Edward J. Gonzalez, Michael J. Davies, Keith D. Kaufman & Barry J. Goldstein. (2013) Efficacy and Safety of Sitagliptin in Patients With Type 2 Diabetes and ESRD Receiving Dialysis: A 54-Week Randomized Trial. American Journal of Kidney Diseases 61:4, pages 579-587.
Crossref
Crossref
Lei Zhang, Mingbo Su, Jingya Li, Xun Ji, Jiang Wang, Zeng Li, Jia Li & Hong Liu. (2013)
Design, Synthesis, Structure-Activity Relationships, and Docking Studies of 1-(γ-1,2,3-Triazol Substituted Prolyl)-(
S
)-3,3-Difluoropyrrolidines as a Novel Series of Potent and Selective Dipeptidyl Peptidase-4 Inhibitors
. Chemical Biology & Drug Design 81:2, pages 198-207.
Crossref
Crossref
Ansarullah, Yan Lu, Martha Holstein, Brittany DeRuyter, Alex Rabinovitch & Zhiguang Guo. (2013) Stimulating β-Cell Regeneration by Combining a GPR119 Agonist with a DPP-IV Inhibitor. PLoS ONE 8:1, pages e53345.
Crossref
Crossref
Antonella de de Campo & Kurt Possnig. 2013. Geriatrische Notfallversorgung. Geriatrische Notfallversorgung
411
431
.
Xiaodong Zhang, Jiang Wang, Mingbo Su, Zeng Li, Jingya Li, Jia Li & Hong Liu. (2012) Discovering Novel α-aminoacyl-Containing Proline Derivatives with Potent and Selective Inhibitory Activity Against Dipeptidyl Peptidase IV: Design, Synthesis, Biological Evaluation, and Molecular Modeling. Chemical Biology & Drug Design 80:6, pages 843-852.
Crossref
Crossref
K. Gooßen & S. Gräber. (2012) Longer term safety of dipeptidyl peptidase‐4 inhibitors in patients with type 2 diabetes mellitus: systematic review and meta‐analysis. Diabetes, Obesity and Metabolism 14:12, pages 1061-1072.
Crossref
Crossref
Miyako Kishimoto & Mitsuhiko Noda. (2012) Effect of the Addition of Sitagliptin and Miglitol on Insulin-Treated Type 2 Diabetes. Diabetes Therapy 3:1.
Crossref
Crossref
Thomas Rauch, Ulrike Graefe-Mody, Carolyn F. Deacon, Arne Ring, Jens J. Holst, Hans-Juergen Woerle, Klaus A. Dugi & Tim Heise. (2012) Linagliptin Increases Incretin Levels, Lowers Glucagon, and Improves Glycemic Control in Type 2 Diabetes Mellitus. Diabetes Therapy 3:1.
Crossref
Crossref
Emma R. Parmee, Ranabir Sinharoy, Feng Xu, Jeffrey C. Givand & Lawrence A. Rosen. 2012. Case Studies in Modern Drug Discovery and Development. Case Studies in Modern Drug Discovery and Development
10
44
.
Ganesh V. Sangle, Lina M. Lauffer, Anthony Grieco, Shivangi Trivedi, Roman Iakoubov & Patricia L. Brubaker. (2012) Novel Biological Action of the Dipeptidylpeptidase-IV Inhibitor, Sitagliptin, as a Glucagon-Like Peptide-1 Secretagogue. Endocrinology 153:2, pages 564-573.
Crossref
Crossref
D. Williams‐Herman, L. Xu, R. Teng, G. T. Golm, J. Johnson, M. J. Davies, K. D. Kaufman & B. J. Goldstein. (2011)
Effect of initial combination therapy with sitagliptin and metformin on
β
‐cell function in patients with type 2 diabetes
. Diabetes, Obesity and Metabolism 14:1, pages 67-76.
Crossref
Crossref
Yoshimasa Aso, Noriyuki Ozeki, Tomoko Terasawa, Rika Naruse, Kenji Hara, Mariko Suetsugu, Kohzo Takebayashi, Mitsuei Shibazaki, Kohsuke Haruki, Kimio Morita & Toshihiko Inukai. (2012) Serum level of soluble CD26/dipeptidyl peptidase-4 (DPP-4) predicts the response to sitagliptin, a DPP-4 inhibitor, in patients with type 2 diabetes controlled inadequately by metformin and/or sulfonylurea. Translational Research 159:1, pages 25-31.
Crossref
Crossref
F. M. Keane, S. Chowdhury, T.-W. Yao, N. A. Nadvi, M. G. Gall, Y. Chen, B. Osborne, A. J. V. Ribeiro, W. B. Church, G. W. McCaughan, M. D. Gorrell & D. M. T. Yu. 2011. Proteinases as Drug Targets. Proteinases as Drug Targets
118
144
.
Jonathan Z. Long & Benjamin F. Cravatt. (2011) The Metabolic Serine Hydrolases and Their Functions in Mammalian Physiology and Disease. Chemical Reviews 111:10, pages 6022-6063.
Crossref
Crossref
Atsunori Kashiwagi, Takashi Kadowaki, Naoko Tajima, Kenji Nonaka, Tadaaki Taniguchi, Mikio Nishii, Juan Camilo Arjona Ferreira & John M Amatruda. (2011) Sitagliptin added to treatment with ongoing pioglitazone for up to 52 weeks improves glycemic control in Japanese patients with type 2 diabetes. Journal of Diabetes Investigation 2:5, pages 381-390.
Crossref
Crossref
Elizabeth Migoya, Patrick Larson, Arthur Bergman, Jutta Miller, Amy O. Johnson-Levonas, Kenneth C. Lasseter & John A. Wagner. (2011) Sitagliptin, a Dipeptidyl Peptidase-4 Inhibitor, Does Not Affect the Pharmacokinetics of Ethinyl Estradiol or Norethindrone in Healthy Female Subjects. The Journal of Clinical Pharmacology 51:9, pages 1319-1325.
Crossref
Crossref
Gary A. Herman, Goutam C. Mistry, Bingming Yi, Arthur J. Bergman, Amy Q. Wang, Wei Zeng, Li Chen, Karen Snyder, Jon L. Ruckle, Patrick J. Larson, Michael J. Davies, Ronald B. Langdon, Keith M. Gottesdiener & John A. Wagner. (2011) Evaluation of pharmacokinetic parameters and dipeptidyl peptidase-4 inhibition following single doses of sitagliptin in healthy, young Japanese males. British Journal of Clinical Pharmacology 71:3, pages 429-436.
Crossref
Crossref
Zafar H Israili. (2011) Advances in the Treatment of Type 2 Diabetes Mellitus. American Journal of Therapeutics 18:2, pages 117-152.
Crossref
Crossref
Yun-Mi JangDong-Lim Kim. (2011) Candidate Dipeptidyl Peptidase-4 Inhibitors for the Treatment of Type 2 Diabetes. Diabetes & Metabolism Journal 35:2, pages 117.
Crossref
Crossref
Ilaria Dicembrini, Laura Pala & Carlo Maria Rotella. (2011) From Theory to Clinical Practice in the Use of GLP-1 Receptor Agonists and DPP-4 Inhibitors Therapy. Experimental Diabetes Research 2011, pages 1-8.
Crossref
Crossref
Shoude Zhang, Weiqiang Lu, Xiaofeng Liu, Yanyan Diao, Fang Bai, Liyan Wang, Lei Shan, Jin Huang, Honglin Li & Weidong Zhang. (2011) Fast and effective identification of the bioactive compounds and their targets from medicinal plants via computational chemical biology approach. MedChemComm 2:6, pages 471.
Crossref
Crossref
Baptist Gallwitz. 2011. Diabetes - Perspectives in Drug Therapy. Diabetes - Perspectives in Drug Therapy
53
74
.
Debora Williams-Herman, Samuel S Engel, Elizabeth Round, Jeremy Johnson, Gregory T Golm, Hua Guo, Bret J Musser, Michael J Davies, Keith D Kaufman & Barry J Goldstein. (2010) Safety and tolerability of sitagliptin in clinical studies: a pooled analysis of data from 10,246 patients with type 2 diabetes. BMC Endocrine Disorders 10:1.
Crossref
Crossref
R. Retnakaran, Y. Qi, C. Opsteen, E. Vivero & B. Zinman. (2010) Initial short‐term intensive insulin therapy as a strategy for evaluating the preservation of beta‐cell function with oral antidiabetic medications: a pilot study with sitagliptin. Diabetes, Obesity and Metabolism 12:10, pages 909-915.
Crossref
Crossref
Wataru Takasawa, Kei Ohnuma, Ryo Hatano, Yuko Endo, Nam H. Dang & Chikao Morimoto. (2010) Inhibition of dipeptidyl peptidase 4 regulates microvascular endothelial growth induced by inflammatory cytokines. Biochemical and Biophysical Research Communications 401:1, pages 7-12.
Crossref
Crossref
Scott D. Edmondson, Feng Xu & Joseph D. ArmstrongIIIIII. 2010. Modern Drug Synthesis. Modern Drug Synthesis
123
140
.
Y. Iwamoto, N. Tajima, T. Kadowaki, K. Nonaka, T. Taniguchi, M. Nishii, J. C. Arjona Ferreira & J. M. Amatruda. (2010) Efficacy and safety of sitagliptin monotherapy compared with voglibose in Japanese patients with type 2 diabetes: a randomized, double-blind trial. Diabetes, Obesity and Metabolism 12:7, pages 613-622.
Crossref
Crossref
Naveen Mulakayala, Upendar Reddy CH, Javed Iqbal & Manojit Pal. (2010) Synthesis of dipeptidyl peptidase-4 inhibitors: a brief overview. Tetrahedron 66:27-28, pages 4919-4938.
Crossref
Crossref
Baptist Gallwitz. (2010) The evolving place of incretin-based therapies in type 2 diabetes. Pediatric Nephrology 25:7, pages 1207-1217.
Crossref
Crossref
D. Williams‐Herman, J. Johnson, R. Teng, G. Golm, K. D. Kaufman, B. J. Goldstein & J. M. Amatruda. (2010) Efficacy and safety of sitagliptin and metformin as initial combination therapy and as monotherapy over 2 years in patients with type 2 diabetes. Diabetes, Obesity and Metabolism 12:5, pages 442-451.
Crossref
Crossref
M. Monami, I. Iacomelli, N. Marchionni & E. Mannucci. (2010) Dipeptydil peptidase-4 inhibitors in type 2 diabetes: A meta-analysis of randomized clinical trials. Nutrition, Metabolism and Cardiovascular Diseases 20:4, pages 224-235.
Crossref
Crossref
Qiaoyi Zhang, Srini Rajagopalan, Panagiotis Mavros, Samuel S. Engel, Michael J. Davies, Donald Yin & Larry Radican. (2010) Differences in baseline characteristics between patients prescribed sitagliptin versus exenatide based on a US electronic medical record database. Advances in Therapy 27:4, pages 223-232.
Crossref
Crossref
P. Aschner, H. L. Katzeff, H. Guo, S. Sunga, D. Williams‐Herman, K. D. Kaufman & B. J. Goldstein. (2010) Efficacy and safety of monotherapy of sitagliptin compared with metformin in patients with type 2 diabetes. Diabetes, Obesity and Metabolism 12:3, pages 252-261.
Crossref
Crossref
Baptist Gallwitz. (2010) DPP‐4‐Inhibitoren in der Klinik. Therapie ohne Hypoglykämie‐Gefahr. Pharmazie in unserer Zeit 39:2, pages 114-118.
Crossref
Crossref
T. Vilsbøll, J. Rosenstock, H. Yki‐Järvinen, W. T. Cefalu, Y. Chen, E. Luo, B. Musser, P. J. Andryuk, Y. Ling, K. D. Kaufman, J. M. Amatruda, S. S. Engel & L. Katz. (2009) Efficacy and safety of sitagliptin when added to insulin therapy in patients with type 2 diabetes. Diabetes, Obesity and Metabolism 12:2, pages 167-177.
Crossref
Crossref
Paul E. Szmitko, Lawrence A. Leiter & Subodh Verma. (2010) The incretin system and cardiometabolic disease. Canadian Journal of Cardiology 26:2, pages 87-95.
Crossref
Crossref
Claude Jaffiol. (2009) Actualité de la prise en charge du diabète de type 2 en France. Bulletin de l'Académie Nationale de Médecine 193:7, pages 1645-1661.
Crossref
Crossref
Joshua J. Neumiller. (2009) Differential chemistry (structure), mechanism of action, and pharmacology of GLP-1 receptor agonists and DPP-4 inhibitors. Journal of the American Pharmacists Association 49:5, pages S16-S29.
Crossref
Crossref
Daniel M. Bloomfield, Rajesh Krishna, David Hreniuk, Lisa Hickey, Kalyan Ghosh, Arthur J. Bergman, Jutta Miller, Maria J. Gutierrez, Randall Stoltz, Keith M. Gottesdiener, Gary A. Herman & John A. Wagner. (2009) A Thorough QTc Study to Assess the Effect of Sitagliptin, a DPP4 Inhibitor, on Ventricular Repolarization in Healthy Subjects. The Journal of Clinical Pharmacology 49:8, pages 937-946.
Crossref
Crossref
Scott D. Edmondson, Anthony Mastracchio, Jason M. Cox, George J. Eiermann, Huaibing He, Kathryn A. Lyons, Reshma A. Patel, Sangita B. Patel, Aleksandr Petrov, Giovanna Scapin, Joseph K. Wu, Shiyao Xu, Bing Zhu, Nancy A. Thornberry, Ranabir Sinha Roy & Ann E. Weber. (2009) Aminopiperidine-fused imidazoles as dipeptidyl peptidase-IV inhibitors. Bioorganic & Medicinal Chemistry Letters 19:15, pages 4097-4101.
Crossref
Crossref
Bo Ahrén. (2009) Clinical results of treating type 2 diabetic patients with sitagliptin, vildagliptin or saxagliptin – diabetes control and potential adverse events. Best Practice & Research Clinical Endocrinology & Metabolism 23:4, pages 487-498.
Crossref
Crossref
Kiwon Ban, Sonya Hui, Daniel J. Drucker & Mansoor Husain. (2009) Cardiovascular consequences of drugs used for the treatment of diabetes: potential promise of incretin—based therapies. Journal of the American Society of Hypertension 3:4, pages 245-259.
Crossref
Crossref
M. Reimann, E. Bonifacio, M. Solimena, P.E.H. Schwarz, B. Ludwig, M. Hanefeld & S.R. Bornstein. (2009) An update on preventive and regenerative therapies in diabetes mellitus. Pharmacology & Therapeutics 121:3, pages 317-331.
Crossref
Crossref
Viswanathan Mohan, Wenying Yang, Ho-Young Son, Lei Xu, Liliane Noble, Ronald B. Langdon, John M. Amatruda, Peter P. Stein & Keith D. Kaufman. (2009) Efficacy and safety of sitagliptin in the treatment of patients with type 2 diabetes in China, India, and Korea. Diabetes Research and Clinical Practice 83:1, pages 106-116.
Crossref
Crossref
Anne-Marie Lambeir, Simon Scharpé & Ingrid De Meester. (2008) DPP4 inhibitors for diabetes—What next?. Biochemical Pharmacology 76:12, pages 1637-1643.
Crossref
Crossref
J. C. N. Chan, R. Scott, J. C. Arjona Ferreira, D. Sheng, E. Gonzalez, M. J. Davies, P. P. Stein, K. D. Kaufman, J. M. Amatruda & D. Williams-Herman. (2008) Safety and efficacy of sitagliptin in patients with type 2 diabetes and chronic renal insufficiency. Diabetes, Obesity and Metabolism 10:7, pages 545-555.
Crossref
Crossref
L. Lauffer, R. Iakoubov & P. L. Brubaker. (2008) GPR119: “Double-Dipping” for Better Glycemic Control. Endocrinology 149:5, pages 2035-2037.
Crossref
Crossref